BioSpace News Archive

Drug Development

Lynk Pharmaceuticals Announces First Patient Dosed in Phase II Clinical Study of LNK01001 in Patients with Ankylosing Spondylitis

Lynk Pharmaceuticals Co., Ltd. announced today that the first patient has been dosed with LNK01001 in its Phase II clinical trial targeting ankylosing spondylitis.

January 19, 2022
·
2 min read
Seegene to Launch New COVID-19 PCR Test with a Reduced Turnaround Time Optimized for Mass Testing

Seegene Inc., South Korea’s leading molecular diagnostics company, announced the upcoming launch of the Allplex™ SARS-CoV-2 Fast PCR Assay, which can deliver PCR results in just 60 minutes.

January 19, 2022
·
3 min read
Deals

Ginkgo Bioworks Announces Acquisition of Massachusetts COVID-19 Testing Provider Project Beacon COVID-19 LLC

Ginkgo Bioworks today announced the acquisition of Project Beacon COVID-19 LLC (Project Beacon), a Boston-based social benefit organization focused on helping to increase the capacity, availability, accessibility and affordability of COVID-19 testing.

January 19, 2022
·
6 min read
Business

Lakewood-Amedex Appoints Chief Medical Officer and Adds New Management Team Members

Lakewood-Amedex Inc. announced that Sumita Paul, MD, MPH, MBA has joined Lakewood-Amedex as Chief Medical Officer and Senior Vice President, Research and Development to lead its recently recruited scientific-clinical management team.

January 19, 2022
·
4 min read
Business

Expansion Therapeutics Appoints Gary Bridger, Ph.D., to Its Board of Directors

Expansion Therapeutics, Inc. today announced the appointment of Gary Bridger, Ph.D., to its Board of Directors, serving as an independent director.

January 19, 2022
·
4 min read
Policy

VFMCRP receives EU approval for Tavneos® for the treatment of ANCA-associated vasculitis

VFMCRP receives EU approval for Tavneos ® for the treatment of ANCA-associated vasculitis.

January 19, 2022
·
4 min read
Business

PepGen Appoints Laurie Keating as Chair of Board of Directors

PepGen, Inc., a company advancing next-generation oligonucleotide therapies for neuromuscular and neurologic diseases, announced that it has appointed Laurie Keating as Chair of the company’s Board of Directors.

January 19, 2022
·
3 min read
FDA

CytomX Therapeutics Announces FDA Clearance of Investigational New Drug Application for CX-904 for the Treatment of Advanced Solid Tumors

CytomX Therapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application for CX-904, an EGFRxCD3 T-cell-engaging bispecific antibody being co-developed by CytomX and Amgen.

January 19, 2022
·
6 min read
Business

ViaCyte Strengthens Management Team with Appointment of Alyssa Levin as Chief Financial Officer and Addition of Lisa Porter, MD, to the Board of Directors

ViaCyte, Inc. today announced the appointment of Alyssa Levin as Chief Financial Officer and addition of Lisa E. Porter, M.D., to its Board of Directors.

January 19, 2022
·
4 min read
Drug Development

VYNE Therapeutics Announces Phase 1b Data for FMX114 from Phase 1b/2a Trial for the Treatment of Mild-to-Moderate Atopic Dermatitis

VYNE Therapeutics Inc. today announced that it has completed the Phase 1b portion of a Phase 1b/2a clinical trial evaluating FMX114 for the treatment of mild-to-moderate atopic dermatitis (AD) (Study VY2021-01).

January 19, 2022
·
9 min read